The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

Abstract Background With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the oncoprotein of CML. HSP90 is an essential chaperone of BCR/ABL and play...

Full description

Bibliographic Details
Main Authors: Dachuan Zeng, Miao Gao, Renren Zheng, Run Qin, Wei He, Suotian Liu, Wei Wei, Zhenglan Huang
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Experimental Hematology & Oncology
Subjects:
BCR/ABL
HSP90 inhibitor
KW-2478
Malignancy
Imatinib resistance
Online Access:https://doi.org/10.1186/s40164-022-00287-w

Internet

https://doi.org/10.1186/s40164-022-00287-w

Similar Items